Mulder, MD, PhD, neonatologist, Antwerp University Hospital, Department of Pediatrics, Division of Neonatology, Antwerp, Belgium
Zucherato et al
Woo et al., 2017)
This guide focuses on the current 30 mL Canadian presentation carrying DIN 00038202 and the U.S
Even when insulin is used, these classes of medications still provide benefits. Joanna Khatib In a meta-analysis, Khatib and colleagues assessed major adverse CV events from eight recent CV outcome trials for SGLT2 inhibitors, GLP-1 receptor agonists and DPP-IV inhibitors: DECLARE, EMPA-REG, EXSCEL, HARMONY, LEADER, SUSTAIN-6, EXAMINE and SAVOR-TIMI 53